ITOC 2022 | Addressing the unmet needs of immunotherapy in bladder cancer

Chong Xian Pan • 29 Sep 2022

ITOC 2022 MAP 2022

Bladder Cancer Genitourinary Cancer

Immuno-Oncology

Chong Xian Pan, MD, PhD, Harvard Medical School, Boston, MA, discusses improving the efficacy of immunotherapy in bladder cancer. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Immunotherapy + chemotherapy for bladder cancer

Chong Xian Pan • 27 Sep 2022

The synergistic antitumor activity of pan-PI3K inhibition and ICI's in bladder cancer

Chong Xian Pan • 29 Sep 2022

Potentiating immunotherapy for bladder cancer via porphyrin-based PLZ4-nanoparticles

Chong Xian Pan • 27 Sep 2022

Related Videos

Improving the current chemotherapy standard: a role for DNA methyltransferase inhibitors

Simon Crabb • 16 Nov 2018

Adverse events in bladder cancer immunotherapy

Jonathan Rosenberg • 18 Jan 2019

How to involve patients in clinical decision making

Joe O'Sullivan • 29 Nov 2018

Cabozantinib plus docetaxel and prednisone in mCRPC

Munjid Al Harthy • 18 Feb 2019